drugset
drugset / Trial / NCT04420975

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT04420975 ↗

Phase 1 Active not recruiting 14 enrolled Jonsson Comprehensive Cancer Center Highlight Therapeutics · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.

Timeline

Start
2020-10-14
Primary completion
2027-01-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BO-112 Oligonucleotide (other) — Other
Subject Nivolumab Monoclonal antibody — Intravenous

Indications

dedifferentiated liposarcoma fibrosarcoma leiomyosarcoma malignant peripheral nerve sheath tumor myxofibrosarcoma pleomorphic rhabdomyosarcoma retroperitoneal sarcoma spindle cell sarcoma synovial sarcoma undifferentiated high grade pleomorphic sarcoma of bone undifferentiated pleomorphic sarcoma, inflammatory variant